Legend Biotech Co. (NASDAQ:LEGN) Shares Purchased by Aigen Investment Management LP

Aigen Investment Management LP grew its stake in shares of Legend Biotech Co. (NASDAQ:LEGN) by 19.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,363 shares of the company’s stock after acquiring an additional 1,206 shares during the period. Aigen Investment Management LP’s holdings in Legend Biotech were worth $240,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Avior Wealth Management LLC lifted its position in shares of Legend Biotech by 3.0% during the third quarter. Avior Wealth Management LLC now owns 11,097 shares of the company’s stock worth $541,000 after purchasing an additional 323 shares during the last quarter. Bridgewater Associates LP lifted its holdings in Legend Biotech by 0.3% during the 3rd quarter. Bridgewater Associates LP now owns 165,975 shares of the company’s stock worth $8,088,000 after buying an additional 516 shares during the last quarter. Advisors Asset Management Inc. grew its position in shares of Legend Biotech by 14.0% in the 3rd quarter. Advisors Asset Management Inc. now owns 6,812 shares of the company’s stock worth $332,000 after acquiring an additional 837 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Legend Biotech by 5.9% in the 4th quarter. Rhumbline Advisers now owns 27,638 shares of the company’s stock valued at $899,000 after acquiring an additional 1,544 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Legend Biotech by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,320 shares of the company’s stock valued at $564,000 after acquiring an additional 1,609 shares during the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Stock Performance

LEGN opened at $35.26 on Monday. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $35.36 and its 200-day moving average is $41.45. The stock has a market cap of $6.44 billion, a PE ratio of -37.12 and a beta of 0.19. Legend Biotech Co. has a twelve month low of $30.17 and a twelve month high of $69.24.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Legend Biotech in a report on Monday, December 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $83.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a research report on Monday, December 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $73.00 target price on shares of Legend Biotech in a report on Tuesday, January 21st. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, Legend Biotech presently has an average rating of “Buy” and a consensus target price of $79.50.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).